HIV viraemia and mother-to-child transmission risk after antiretroviral therapy initiation in pregnancy in Cape Town, South Africa

HIV Medicine

Volumn 18, Issue 2, 2017, Pages 80-88

  Myer, L ^a   Phillips, T K ^a   McIntyre, J A ^a,b   Hsiao, N Y ^c   Petro, G ^a   Zerbe, A ^d   Ramjith, J ^a   Bekker, L G ^a   Abrams, E J ^d,e  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b ANOVA HEALTH INSTITUTE   (South Africa)

^c NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^d Columbia University Mailman School of Public Health ^*  (United States)

^e Columbia University ^*  (United States)

Author keywords

antiretroviral therapy; HIV; mother to child transmission; pregnancy; viral load.

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NEVIRAPINE; VIRUS RNA; ZIDOVUDINE; ANTIRETROVIRUS AGENT;

ADULT; ANTIRETROVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; DRUG EXPOSURE; FEMALE; FOLLOW UP; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PREGNANCY; PREGNANT WOMAN; PRENATAL CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUERPERIUM; SINGLE DRUG DOSE; SOUTH AFRICA; TREATMENT DURATION; TUBERCULOSIS; VERTICAL TRANSMISSION; VIREMIA; VIRUS LOAD; YOUNG ADULT; ADOLESCENT; HIV INFECTIONS; LONGITUDINAL STUDY; NEWBORN; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVENTION AND CONTROL; RISK ASSESSMENT; VIROLOGY;

ADOLESCENT; ADULT; ANTI-RETROVIRAL AGENTS; FEMALE; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; LONGITUDINAL STUDIES; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SOUTH AFRICA; VIRAL LOAD; YOUNG ADULT;

EID: 84994311412     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12397     Document Type: Article

References (26)

1. Abrams EJ, Myer L. Can we achieve an AIDS-free generation? Perspectives on the global campaign to eliminate new pediatric HIV infections. J Acquir Immune Defic Syndr 2013; 63 (Suppl 2): S208–S212.
2. Thea DM, Steketee RW, Pliner V et al. The effect of maternal viral load on the risk of perinatal transmission of HIV-1. New York City Perinatal HIV Transmission Collaborative Study Group. AIDS 1997; 11: 437–444.
3. John GC, Nduati RW, Mbori-Ngacha DA et al. Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections. J Infect Dis 2001; 183: 206–212.
4. World Health Organization. Consolidated Guidelines on the use of Antiretroviral Drugs for Treating and Preventing HIV Infection. Geneva, WHO, 2013.
5. Townsend CL, Byrne L, Cortina-Borja M et al. Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000–2011. AIDS 2014; 28: 1049–1057.
6. Katz IT, Leister E, Kacanek D et al. Factors associated with lack of viral suppression at delivery among highly active antiretroviral therapy-naive women with HIV: a cohort study. Ann Intern Med 2015; 162: 90–99.
7. Read PJ, Mandalia S, Khan P et al. When should HAART be initiated in pregnancy to achieve an undetectable HIV viral load by delivery? AIDS 2012; 26:1095–1103.
8. European Collaborative Study, Patel D, Cortina-Borja M, Thorne C, Newell ML. Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women. Clin Infect Dis 2007; 44:1647–1656.
9. UNICEF. Towards and AIDS-free generation: Children and AIDS 6th Stocktaking Report. New York, UNICEF, 2013
10. Myer L, Phillips T, Manuelli V, McIntyre J, Bekker LG, Abrams EJ. Evolution of antiretroviral therapy services for HIV-infected pregnant women in Cape Town, South Africa. J Acquir Immune Defic Syndr 2015;69 (2):e57–e65.
11. Myer L, Daskilewicz K, McIntyre J, Bekker LG. Comparison of point-of-care versus laboratory-based CD4 cell enumeration in HIV-positive pregnant women. J Int AIDS Soc 2013; 16: 18649.
12. World Health Organization. Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants: Recommendations for a Public Health Approach. Geneva, WHO, 2010.
13. McCullagh P, Nelder JA. Generalized Linear Models. New York, Chapman & Hall/CRC, 1999.
14. Okonji JA, Zeh C, Weidle PJ et al. CD4, viral load response, and adherence among antiretroviral-naïve breast-feeding women receiving triple antiretroviral prophylaxis for prevention of mother-to-child transmission of HIV in Kisumu, Kenya. J Acquir Immune Defic Syndr 2012; 61: 249–257.
15. Palombi L, Marazzi MC, Voetberg A, Magid NA. Treatment acceleration program and the experience of the DREAM program in prevention of mother-to-child transmission of HIV. AIDS 2007; 21 (Suppl 4): S65–S71.
16. Wu H, Kuritzkes DR, McClernon DR et al. Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virologic end points. J Infect Dis 1999; 179: 799–807.
17. Mandelbrot L, Tubiana R, Le CJ et al. No perinatal HIV-1 transmission from women with effective antiretroviral Therapy starting before conception. Clin Infect Dis 2015;61:1715–1725.
18. de Ruiter A, Taylor GP, Clayden P et al. British HIV Association guidelines for the management of HIV infection in pregnancy women, 2012 (2014 interim review). HIV Med 2014; 14 (Suppl 4): 1–77.
19. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf. (accessed 19 December 2015).
20. Grennan JT, Loutfy MR, Su D et al. Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis. J Infect Dis 2012; 205:1230–1238.
21. Ryscavage P, Kelly S, Li JZ, Harrigan PR, Taiwo B. Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients. Antimicrob Agents Chemother 2014; 58: 3585–3598.
22. Statistics South Africa. Perinatal Deaths in South Africa, 2011–2013. Pretoria, Statistics South Africa, 2015.
23. Lockman S, Hughes M, Sawe F et al. Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial. PLoS Med 2012; 9: e1001236.
24. Myer L. Initiating antiretroviral therapy in pregnancy: the importance of timing. J Acquir Immune Defic Syndr 2011; 58: 125–126.
25. Westling K, Pettersson K, Kaldma A et al. Rapid decline in HIV viral load when introducing raltegravir-containing antiretroviral treatment late in pregnancy. AIDS Patient Care STDS 2012; 26: 714–717.
26. Watts DH, Stek A, Best BM et al. Raltegravir pharmacokinetics during pregnancy. J Acquir Immune Defic Syndr 2014; 67: 375–381.